Failing to meet the primary endpoint in its confirmatory phase III Embark trial, Sarepta Therapeutics Inc.’s gene therapy, Elevidys (delandistrogene moxeparvovec), which received accelerated approval in June and was priced at $3.2 million, has one of three fates in its future, all of which are dependent on how the U.S. FDA perceives the data.
EMBARK is offering an express bus route from downtown Oklahoma City to the state fairgrounds from 9:30 a.m. to 11:30 p.m. on Saturday, September 16, and Sunday, September 17.